Printer Friendly

ONE OF THE FIRST GENERIC VERSIONS OF TOP-SELLING ANTI-ANXIETY AGENT OFFERS LOWER-COST TREATMENT OPTION FOR MORE THAN 1 MILLION PATIENTS

 WAYNE, N.J., Oct. 19 /PRNewswire/ -- A lower-cost alternative will be available for the more than 1 million U.S. patients who currently take The Upjohn Company's branded top-selling anti-anxiety agent, Xanax(R), and to the physicians who treat them. Lederle Standard Products received Food and Drug Administration (FDA) approval to market the generic version of Xanax, Alprazolam Tablets, beginning Wednesday, Oct. 20 when the Xanax patent expires. Lederle Standard Products is the only company to receive FDA approval for all four strengths marketed by the innovator. Lederle's Alprazolam is as safe and effective as Xanax, but is priced less than the branded product.
 A switch by the current 1 million Xanax patients in the United States to Lederle's Alprazolam could result in a potential annual savings of approximately $330 to each individual, and over $158 million to the U.S. health care system. Xanax is the largest selling anti-anxiety drug in its class accounting for almost 50 percent of its market.
 Alprazolam is indicated for the management of anxiety disorder or the short-term relief of symptoms of anxiety.
 Alprazolam joins the existing line of Lederle Standard products, which includes recently approved generic versions of the cardiovascular therapies Cardizem(R) (Diltiazem tablets) and Tenormin(R) (Atenolol tablets), the nonsteroidal anti-inflammatory drug (NSAID) Orudis(R) (Ketoprofen capsules) and most recently the cholesterol-lowering agent Lopid(R) (Gemfibrozil tablets) and the antibiotic VANCOCYN(R) (vancomycin for oral solution). Additionally, Lederle Standard Products plans to launch a generic version of another one of the largest branded products to come off patent, the NSAID Naprosyn(R) (Naproxen tablets), which goes off patent Dec. 21, 1993.
 "Alprazolam is one more example of Lederle's commitment to aggressively pursue FDA approval to manufacture and market generic versions of widely prescribed branded pharmaceuticals as soon as they come off patent," said Frank Condella, vice president and general manager of Lederle Standard Products. "Lederle Standard Products is dedicated to providing patients in the U.S. with high-quality, low-cost generic alternatives, such as Alprazolam." The Lederle Standard Products label, established 20 years ago, represents generic alternatives for more than 60 chemical entities in over 200 package styles.
 Lederle Laboratories, a division of American Cyanamid Company (NYSE: ACY), is a research-intensive organization that manufactures and markets worldwide a broad range of health care products, including branded pharmaceuticals, generics, vitamins and nutritionals.
 -0- 10/19/93
 /CONTACT: Pat Fiaschetti, 201-831-4684, for Lederle/
 (ACY)


CO: Lederle Standard Products ST: New Jersey IN: MTC SU:

CK -- NYFNS2 -- 3701 10/19/93 07:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 19, 1993
Words:419
Previous Article:SPORTS-UTILITIES WILL HEAT UP SUNROOF SALES ACCORDING TO LEADING SUNROOF MANUFACTURER
Next Article:INFRASONICS ANNOUNCES RESULTS FOR FIRST QUARTER
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters